BioWorld

Jan. 9, 2004

Opportunistic Axonyx Raises $50M Through Public Market

Months after raising $25 million in a private placement, Axonyx Inc. is at it again. But this time, Axonyx has set its sights higher, looking to bring in $50 million. (BioWorld Today) Read More

Novacea Series C Gets $35M To Push Cancer Compounds

Myogen Begins Enrollment For Ambrisentan Phase III Studies

Esperion Gets $32.2M From Settlement With Stockholder

Keryx Acquiring Three Phase II Drugs In 'Success-Based' Buyout

With 'Hybrid' Business Model, Infinity Signs Amgen To Deal

ImmunoGen Moving Forward Alone With Cancer Products

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 23, 2026.

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...